Abeona Therapeutics Inc. (ABEO)
NASDAQ: ABEOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ABEO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $165.31M
- EPS (TTM)
- -$1.16
- Dividend yield
- None
- Ex-dividend date
- Mar 31, 2000
- 52-week range
- 2.09 – 7.65
- Day range
- 2.40 – 2.57
- Volume / Avg
- 4.72M / 1.66M
- Beta
- —
- Shares outstanding
- 68.31M
52-week range
ABEO stock today
Shares of Abeona Therapeutics (ABEO) finished lower on Nov 20 at $2.42, a drop of 1.22% or $0.03 per share, versus the S&P 500's 3.70% decline. Volume was 2.8x the average at 4.72M shares, a sign of unusually heavy trading. Shares are 68.4% below their 52-week high of $7.65, set on Aug 11, 2026 and 15.8% above the 52-week low of $2.09, near the bottom of the past year's range.
ABEO is down 54.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 46.0%. Abeona Therapeutics has posted a net loss over the last twelve months (EPS of -$1.16), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Abeona Therapeutics
Company profileAbeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Vishwas Seshadri M.B.A., Ph.D.
- Headquarters
- Cleveland, OH
- Employees
- 226
- Website
- abeonatherapeutics.com
Financial highlights
Full financialsIn fiscal 2025, Abeona Therapeutics generated $5.8 million in revenue. Net income was $71.2 million, for a net margin of 1223.1% versus a median of -2177.8% in the prior 5 years. Gross margin was 73.7% and operating margin -1536.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $5.82M | — | $3.50M | $1.41M | $3.00M |
| Growth | — | — | +147.52% | -52.87% | -70.00% |
| Net income | $71.18M | $-63.73M | $-54.19M | $-39.70M | $-84.94M |
| EPS (diluted) | $1.01 | $-1.55 | $-2.53 | $-5.53 | $-0.86 |
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$15.56+542.98%
- Strong buy 0
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.08 vs $-0.14
- Surprise
- +42.86%
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $3,706.25
- Ex-dividend date
- Mar 31, 2000
ABEO news
All ABEO news- Abeona Therapeutics® Announces Participation in Upcoming Investor ConferencesGlobeNewswire
- Abeona Therapeutics (ABEO) Q3 2026 Earnings Call TranscriptNasdaqABEO, ET
- Abeona Therapeutics Reports Q3 Net ZEVASKYN Revenue of $13.5 million and Acquisition of ABO-801Nasdaq
- Abeona Therapeutics Inc. Acquires Phase 3-Ready APT-1011 and Enters Into Agreement for $30 Million Private PlacementNasdaq
- Abeona Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial ProgressGlobeNewswire
- Abeona Therapeutics® Acquires Phase 3-Ready APT-1011, Now ABO-801, and Enters Into Agreement for $30 Million Private PlacementGlobeNewswire
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Weekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus StudyNasdaqABBV, ABEO, AMRX, ANIP
Abeona Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KRROKorro Bio Inc. | 12.18 | -0.08% | $167.18M | vs ABEO |
| TRDAEntrada Therapeutics Inc. | 4.35 | -6.25% | $170.30M | vs ABEO |
| EMISEmmis Acquisition Corp. Class A | 10.36 | +0.15% | $163.36M | vs ABEO |
| SIGASIGA Technologies Inc. | 2.40 | -9.43% | $172.45M | vs ABEO |
| VOGXVogenx Inc | 11.87 | -7.30% | $176.33M | vs ABEO |
| NATRNature's Sunshine Products Inc. | 10.18 | +0.10% | $176.41M | vs ABEO |
| ORMPOramed Pharmaceuticals Inc. | 3.57 | -3.25% | $155.24M | vs ABEO |
| ADCTADC Therapeutics SA | 1.28 | -1.54% | $180.05M | vs ABEO |
Indexes, lists and sector
Abeona Therapeutics stock FAQ
What is Abeona Therapeutics's stock price today?
ABEO last traded at $2.42 as of Nov 20, 4:00 PM EST, down 1.22% on the day. Prices are delayed at least 15 minutes.
Does Abeona Therapeutics pay a dividend?
Yes. Abeona Therapeutics pays $0.00 per share annually. The most recent dividend of $3,706.25 had an ex-dividend date of Mar 31, 2000.
Who is Abeona Therapeutics's CEO?
Dr. Vishwas Seshadri M.B.A., Ph.D. is the chief executive officer of Abeona Therapeutics Inc., which has about 226 employees.
Has ABEO ever split its stock?
Yes. The most recent ABEO stock split was a 1-for-25 split on Jul 5, 2022, one of 5 splits on record.
What is the ABEO 52-week high?
The 52-week high for ABEO is $7.65 and the 52-week low is $2.09. The stock is currently 68.4% below its high.